Gilead Sciences (GILD) Tops Q1 EPS by 15c, Reiterate Guidance
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
EPS Growth %: -462.7%
Financial Fact:
Income from operations: 4.4B
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q1 EPS of $1.76, $0.15 better than the analyst estimate of $1.61. Revenue for the quarter came in at $5.3 billion versus the consensus estimate of $5.3 billion.
- Full Year 2019 Guidance Reiterated
Gilead reiterates its full year 2019 guidance, initially provided on February 4, 2019. The guidance for product sales reflects the anticipated entry of generic versions of Letairis and Ranexa in the United States and the full year impact of generic products containing tenofovir disoproxil fumarate in certain European countries.
| (In millions, except percentages and per share amounts) | � | Initially Provided February 4, 2019 |
| Net Product Sales | $21,300 - $21,800 | |
| Non-GAAP | ||
| Product Gross Margin | 85% - 87% | |
| R&D Expenses | $3,600 - $3,800 | |
| SG&A Expenses | $3,900 - $4,100 | |
| Effective Tax Rate | 20.0% - 21.0% | |
| Diluted EPS Impact of Acquisition-related, Up-front Collaboration, Stock-based Compensation and Other Expenses | $1.40 - $1.50 |
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Morgan Stanley lifts server market TAM to $809B, boosts targets on compute stocks
- Goldman "broadly" raises estimates for LTL and truckload stocks
Create E-mail Alert Related Categories
Earnings, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
